<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?subarticle report27466?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gates Open Res</journal-id><journal-id journal-id-type="iso-abbrev">Gates Open Res</journal-id><journal-id journal-id-type="pmc">Gates Open Res</journal-id><journal-title-group><journal-title>Gates Open Research</journal-title></journal-title-group><issn pub-type="epub">2572-4754</issn><publisher><publisher-name>F1000 Research Limited</publisher-name><publisher-loc>London, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6640003</article-id><article-id pub-id-type="doi">10.12688/gatesopenres.13034.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Note</subject></subj-group><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Cross-sectional study of IgG antibody levels to invasive nontyphoidal
<italic>Salmonella</italic> LPS O-antigen with age in Uganda</article-title><fn-group content-type="pub-status"><fn><p>[version 1; peer review: 2 approved, 2 approved with reservations]</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stockdale</surname><given-names>Lisa</given-names></name><role content-type="http://credit.casrai.org/">Formal Analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft Preparation</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2576-8783</contrib-id><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nalwoga</surname><given-names>Angela</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8259-4735</contrib-id><xref ref-type="aff" rid="a2">2</xref><xref ref-type="aff" rid="a3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nash</surname><given-names>Stephen</given-names></name><role content-type="http://credit.casrai.org/">Formal Analysis</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2086-1740</contrib-id><xref ref-type="aff" rid="a3">3</xref></contrib><contrib contrib-type="author"><name><surname>Elias</surname><given-names>Sean</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6053-8238</contrib-id><xref ref-type="aff" rid="a4">4</xref></contrib><contrib contrib-type="author"><name><surname>Asiki</surname><given-names>Gershim</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kusemererwa</surname><given-names>Sylvia</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gilchrist</surname><given-names>James J.</given-names></name><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Newton</surname><given-names>Robert</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><xref ref-type="aff" rid="a2">2</xref><xref ref-type="aff" rid="a5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>MacLennan</surname><given-names>Calman A.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><xref ref-type="aff" rid="a4">4</xref></contrib><aff id="a1">
<label>1</label>Department of Paediatrics, University of Oxford, Oxford, OX3 7LE, UK</aff><aff id="a2">
<label>2</label>MRC/UVRI and LSHTM Uganda Research Institute, Entebbe, Uganda</aff><aff id="a3">
<label>3</label>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK</aff><aff id="a4">
<label>4</label>Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK</aff><aff id="a5">
<label>5</label>Clinical Epidemiology, University of York, York, UK</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xlink:href="mailto:lisa.stockdale@paediatrics.ox.ac.uk">lisa.stockdale@paediatrics.ox.ac.uk</email></corresp><fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>3</volume><elocation-id>1501</elocation-id><history><date date-type="accepted"><day>14</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2019 Stockdale L et al.</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="gatesopenres-3-14147.pdf"/><abstract><p>Invasive nontyphoidal
<italic>Salmonella</italic> (iNTS) disease is a major cause of deaths among children and HIV-infected individuals in sub-Saharan Africa. Acquisition of IgG to iNTS lipopolysaccharide (LPS) O-antigen in Malawi in early childhood corresponds with a fall in cases of iNTS disease suggesting that vaccines able to induce such antibodies could confer protection. To better understand the acquisition of IgG to iNTS in other African settings, we performed a cross-sectional seroepidemiological study using sera from 1090 Ugandan individuals aged from infancy to old age. Sera were analysed for IgG to LPS O-antigen of
<italic>S</italic>. Typhimurium and
<italic>S</italic>. Enteritidis using an in-house ELISA. Below 18 months of age, most children lacked IgG to both serovars. Thereafter, specific IgG levels increased with age, peaking in adulthood, and did not wane noticeably in old age. There was no clear difference in antibody levels between the sexes and the few HIV-infected individuals in the study did not have obviously different levels from uninfected subjects. While IgG to iNTS is acquired at a younger age in Malawian compared with Ugandan children, it is not clear whether this is due to differences in the populations themselves, their exposure to iNTS, or variations between assays used. In conclusion, there is a need to develop a harmonised method and standards for measuring antibodies to iNTS across studies and to investigate acquisition of such antibodies with age across different sites in sub-Saharan Africa.</p></abstract><kwd-group kwd-group-type="author"><kwd>non-typhoidal salmonella</kwd><kwd>NTS</kwd><kwd>antibody</kwd><kwd>Uganda</kwd></kwd-group><funding-group><award-group id="fund-1" xlink:href="http://dx.doi.org/10.13039/501100000265"><funding-source>Medical Research Council</funding-source><award-id>MR/J003999/1</award-id><award-id>MR/K012126/1</award-id></award-group><award-group id="fund-2" xlink:href="http://dx.doi.org/10.13039/501100002992"><funding-source>Department for International Development, UK Government</funding-source></award-group><award-group id="fund-3" xlink:href="http://www.gatesfoundation.org"><funding-source>Gates Foundation</funding-source><award-id>OPP1148489</award-id></award-group><funding-statement>This work was supported by the UK Medical Research Council (MRC): grant number MR/ J003999/1 to LS, grant number MR/K012126/1 to SN, and the Bill and Melinda Gates Foundation (BMGF): grant number OPP1148489 to CM. The Ugandan General Population Cohort study is jointly funded by the UKMRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement. </funding-statement><funding-statement><italic>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</italic></funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Invasive non-typhoidal
<italic>Salmonella</italic> (iNTS) disease is principally caused by serovars
<italic>S</italic>. Typhimurium and
<italic>S</italic>. Enteritidis and is thought to be responsible for up to 680,000 deaths annually, with Africa accounting for more than half of cases
<sup><xref rid="ref-1" ref-type="bibr">1</xref></sup>. Much of this burden is in children under 5 years and HIV-infected adults. In view of this major global burden of disease, and rapid emergence of multidrug resistant iNTS strains
<sup><xref rid="ref-2" ref-type="bibr">2</xref></sup>, development of a vaccine is increasingly vital
<sup><xref rid="ref-3" ref-type="bibr">3</xref></sup>.</p><p>Studies in Malawian children indicate that anti-
<italic>S. Typhimurium</italic> antibodies, notably IgG to O-antigen of LPS and flagellin, and serum bactericidal activity rises rapidly with age in the first few years of life corresponding with a fall in cases of iNTS disease
<sup><xref rid="ref-4" ref-type="bibr">4</xref>,
<xref rid="ref-5" ref-type="bibr">5</xref></sup>. One study found a positive correlation between serum bactericidal assay (SBA) killing and acquisition of anti-LPS IgG
<sup><xref rid="ref-5" ref-type="bibr">5</xref></sup>. However, there is no standardised assay for measurement of iNTS-specific IgG, and the clinical significance of the iNTS SBA is unknown. Given that incidence of iNTS disease drops in children over 2 years, it has been suggested that a rise in specific antibodies and bactericidal activity correlates with protection. This hypothesis is complicated by the observation that among HIV-infected Malawian adults, high LPS-specific IgG was associated with a lack of
<italic>in vitro</italic> bacterial killing
<sup><xref rid="ref-6" ref-type="bibr">6</xref></sup>.</p></sec><sec sec-type="methods"><title>Methods</title><p>In a cross-sectional study, we investigated NTS-specific antibody responses in the rural Ugandan General Population Cohort (GPC)
<sup><xref rid="ref-7" ref-type="bibr">7</xref></sup>. Levels of IgG against serovars
<italic>S</italic>. Typhimurium and
<italic>S</italic>. Enteritidis LPS O-antigens were measured using a standardised in-house ELISA in stored sera from a cross-section of 1,090 Ugandans of all ages, 10 of whom were HIV-infected. Sera from adults (&#x02265; 16 years) were collected from January 2014 to November 2015, and children (&#x0003c;16 years) from January 2016 to November 2017. Antibody units (AU) were calculated using Gen5 software (version 2.0) using a five-parameter logistic (5PL) curve generated with a standard serum from an iNTS-exposed individual. Sera were defined as seronegative if below the lower limit of detection (4 AU for
<italic>S.</italic> Typhimurium and 5 AU for
<italic>S.</italic> Enteritidis) at 1:100 serum dilution.</p><p>Written informed consent for the use of clinical records and biological samples for research purposes was obtained from all GPC participants following Uganda National Council of Science and Technology guidelines. Ethical approval for the use of samples for this study was obtained from The UVRI Research and Ethics Committee and from the Uganda Council for Science and Technology (Ref: GC/127/19/10/710).</p></sec><sec sec-type="results | discussion"><title>Results and discussion</title><p>In this assay, overall O-antigen seropositivity was 82% for
<italic>S.</italic> Typhimurium, and was 70% for
<italic>S.</italic> Enteritidis. Levels of antibody were undetectable in at least 50% of children until 18 months for both serovars and a similar pattern of increasing IgG level was observed with increasing age (
<xref ref-type="fig" rid="f1">Figure 1A, B</xref>). There were no observable differences in antibody levels by sex (
<xref ref-type="fig" rid="f1">Figure 1C, D</xref>). HIV-infected individuals did not have notably high IgG antibody responses, although the study was not powered to demonstrate this.</p><fig fig-type="figure" id="f1" orientation="portrait" position="anchor"><label>Figure 1. </label><caption><p>Plots showing antibody units (AU) for S. Typhimurium (
<bold>A</bold> and
<bold>C</bold>) and S. Enteritidis (
<bold>B</bold> and
<bold>D</bold>) by age. Orange dots indicate HIV infected individuals. (
<bold>A</bold>,
<bold>B</bold>). Females are indicated in red and males in blue (
<bold>C</bold>,
<bold>D</bold>). The box shows the interquartile range (IQR) with middle line representing the median. The whiskers represent the adjacent values, defined as 1.5 &#x000d7; IQR from the edge of the box, with values outside this range shown individually. LLOQ, lower limit of quantification.</p></caption><graphic xlink:href="gatesopenres-3-14147-g0000"/></fig><p>Although performed using a flow cytometric assay, previously published data from Malawi suggest that NTS-specific IgG is present in the majority of children throughout infancy
<sup><xref rid="ref-4" ref-type="bibr">4</xref></sup>, contrasting with our results from Uganda. This could be due to variation in exposure to iNTS in Uganda compared to Malawi, or differences in assays. However, burden of, and exposure to, iNTS disease in Uganda is not well understood. A standardised assay is key to understanding variation in exposure across geographic locations to support vaccine development.</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>Open Science Framework: Invasive Non-Typhoidal Salmonella serology in Uganda.
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17605/OSF.IO/68BYT">https://doi.org/10.17605/OSF.IO/68BYT</ext-link>
<sup><xref rid="ref-8" ref-type="bibr">8</xref></sup>.</p><p>This project contains the age, sex, antibody levels, HIV status and
<italic>Salmonella</italic> status of each participant.</p><p>Data are available under the terms of the
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons Zero "No rights reserved" data waiver</ext-link> (CC0 1.0 Public domain dedication).</p></sec></body><back><ref-list><ref id="ref-1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ao</surname><given-names>TT</given-names></name><name><surname>Feasey</surname><given-names>NA</given-names></name><name><surname>Gordon</surname><given-names>MA</given-names></name><etal/></person-group>:
<article-title>Global burden of invasive nontyphoidal
<italic>Salmonella</italic> disease, 2010.</article-title>
<source><italic toggle="yes">Emerg Infect Dis.</italic></source>
<year>2015</year>;<volume>21</volume>(<issue>6</issue>):<fpage>941</fpage>&#x02013;<lpage>949</lpage>.
<pub-id pub-id-type="doi">10.3201/eid2106.140999</pub-id>
<!--<pub-id pub-id-type="pmcid">4451910</pub-id>-->
<?supplied-pmid 25860298?><pub-id pub-id-type="pmid">25860298</pub-id></mixed-citation></ref><ref id="ref-2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oneko</surname><given-names>M</given-names></name><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Muturi-Kioi</surname><given-names>V</given-names></name><etal/></person-group>:
<article-title>Emergence of Community-Acquired, Multidrug-Resistant Invasive Nontyphoidal
<italic>Salmonella</italic> Disease in Rural Western Kenya, 2009-2013.</article-title>
<source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2015</year>;<volume>61 Suppl 4</volume>:<fpage>S310</fpage>&#x02013;<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1093/cid/civ674</pub-id>
<?supplied-pmid 26449946?><pub-id pub-id-type="pmid">26449946</pub-id></mixed-citation></ref><ref id="ref-3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilchrist</surname><given-names>JJ</given-names></name><name><surname>MacLennan</surname><given-names>CA</given-names></name></person-group>:
<article-title>Invasive Nontyphoidal
<italic>Salmonella</italic> Disease in Africa.</article-title>
<source><italic toggle="yes">EcoSal Plus.</italic></source>
<year>2019</year>;<volume>8</volume>(<issue>2</issue>).
<pub-id pub-id-type="doi">10.1128/ecosalplus.ESP-0007-2018</pub-id>
<?supplied-pmid 30657108?><pub-id pub-id-type="pmid">30657108</pub-id></mixed-citation></ref><ref id="ref-4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacLennan</surname><given-names>CA</given-names></name><name><surname>Gondwe</surname><given-names>EN</given-names></name><name><surname>Msefula</surname><given-names>CL</given-names></name><etal/></person-group>:
<article-title>The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of
<italic>Salmonella</italic> in African children.</article-title>
<source><italic toggle="yes">J Clin Invest.</italic></source>
<year>2008</year>;<volume>118</volume>(<issue>4</issue>):<fpage>1553</fpage>&#x02013;<lpage>1562</lpage>.
<pub-id pub-id-type="doi">10.1172/JCI33998</pub-id>
<!--<pub-id pub-id-type="pmcid">2268878</pub-id>-->
<?supplied-pmid 18357343?><pub-id pub-id-type="pmid">18357343</pub-id></mixed-citation></ref><ref id="ref-5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nyirenda</surname><given-names>TS</given-names></name><name><surname>Gilchrist</surname><given-names>JJ</given-names></name><name><surname>Feasey</surname><given-names>NA</given-names></name><etal/></person-group>:
<article-title>Sequential acquisition of T cells and antibodies to nontyphoidal
<italic>Salmonella</italic> in Malawian children.</article-title>
<source><italic toggle="yes">J Infect Dis.</italic></source>
<year>2014</year>;<volume>210</volume>(<issue>1</issue>):<fpage>56</fpage>&#x02013;<lpage>64</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiu045</pub-id>
<!--<pub-id pub-id-type="pmcid">4054899</pub-id>-->
<?supplied-pmid 24443544?><pub-id pub-id-type="pmid">24443544</pub-id></mixed-citation></ref><ref id="ref-6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maclennan</surname><given-names>CA</given-names></name><name><surname>Gilchrist</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>MA</given-names></name><etal/></person-group>:
<article-title>Dysregulated humoral immunity to nontyphoidal
<italic>Salmonella</italic> in HIV-infected African adults.</article-title>
<source><italic toggle="yes">Science.</italic></source>
<year>2010</year>;<volume>328</volume>(<issue>5977</issue>):<fpage>508</fpage>&#x02013;<lpage>512</lpage>.
<pub-id pub-id-type="doi">10.1126/science.1180346</pub-id>
<!--<pub-id pub-id-type="pmcid">3772309</pub-id>-->
<?supplied-pmid 20413503?><pub-id pub-id-type="pmid">20413503</pub-id></mixed-citation></ref><ref id="ref-7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asiki</surname><given-names>G</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Nakiyingi-Miiro</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies.</article-title>
<source><italic toggle="yes">Int J Epidemiol.</italic></source>
<year>2013</year>;<volume>42</volume>(<issue>1</issue>):<fpage>129</fpage>&#x02013;<lpage>141</lpage>.
<pub-id pub-id-type="doi">10.1093/ije/dys234</pub-id>
<!--<pub-id pub-id-type="pmcid">3600628</pub-id>-->
<?supplied-pmid 23364209?><pub-id pub-id-type="pmid">23364209</pub-id></mixed-citation></ref><ref id="ref-8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stockdale</surname><given-names>L</given-names></name></person-group>:
<article-title>Invasive Non-Typhoidal
<italic>Salmonella</italic> serology in Uganda</article-title>.<year>2019</year>
<pub-id pub-id-type="doi">10.17605/OSF.IO/68BYT</pub-id>
</mixed-citation></ref></ref-list></back><sub-article id="report27466" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/gatesopenres.14147.r27466</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Simuyandi</surname><given-names>Michelo</given-names></name><xref ref-type="aff" rid="r27466a1">1</xref><role>Referee</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7348-2835</contrib-id></contrib><aff id="r27466a1">
<label>1</label>Enteric Disease and Vaccine Research Unit, Centre for Infectious Disease Research in Zambia&#x000a0;(CIDRZ), Lusaka, Zambia</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>7</month><year>2019</year></pub-date><permissions><copyright-statement>Copyright: &#x000a9; 2019 Simuyandi M</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="peer-reviewed-article" id="d35e882" ext-link-type="doi" xlink:href="10.12688/gatesopenres.13034.1"/><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve-with-reservations</meta-value></custom-meta></custom-meta-group></front-stub><body><p>The article describes an important aspect of research which needs more data. Knowing when children are exposed to salmonella infection can inform schedules for vaccination and other control interventions.
<list list-type="order"><list-item><p>The aim of the study should be clear, given the limitation in the standardized method for immunological assessment (I suspect it was to determine the kinetics of antibody acquisition by age). The differences in assays could be discussed in the limitations and maybe how the difference can affect the date explained as well.&#x000a0;</p></list-item><list-item><p>The assay is not described (just called in house) - reviewers could have advised how best to analyse or interpret the data. Did they try to do an EQA with another lab that used a different method to maybe determine concordance?</p></list-item><list-item><p>While the infants in this study have antibodies much later than Malawi, it is not clear if the mean concentrations increase with time or if it is just the number(%) (i.e. positivity&#x000a0;rates) of participants with antibodies that increase over time. The authors could have compared the reported concentrations between the countries.</p></list-item></list>
</p><p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p></body></sub-article><sub-article id="report27468" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/gatesopenres.14147.r27468</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baliban</surname><given-names>Scott M.</given-names></name><xref ref-type="aff" rid="r27468a1">1</xref><role>Referee</role></contrib><aff id="r27468a1">
<label>1</label>Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, USA</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>7</month><year>2019</year></pub-date><permissions><copyright-statement>Copyright: &#x000a9; 2019 Baliban SM</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="peer-reviewed-article" id="d35e950" ext-link-type="doi" xlink:href="10.12688/gatesopenres.13034.1"/><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve-with-reservations</meta-value></custom-meta></custom-meta-group></front-stub><body><p>This study aims to assess the presence of serum IgG to S. Enteritidis and Typhimurium by age and sex in a broad Ugandan cohort. It is of value because the sero-epidemiology of NTS in Uganda, as opposed to other African countries, is not well understood.
<list list-type="order"><list-item><p>More detail is needed for the in-house ELISA. Presumably, it was conducted with purified OPS, as with other studies from this group (e.g. Fiorino
<italic>et al.</italic>, 2017
<sup><xref rid="rep-ref-27468-1" ref-type="bibr">1</xref></sup>). At the moment, it is not clear whether the serum IgG responses are directed against the OPS (and therefore serogroup B/D-specific) as opposed to the core oligosaccharide or lipid A (all other NTS). What is an Antibody Unit?</p></list-item><list-item><p>The authors mention that the lack of seroconversion to OAg-specific IgG in Ugandan children could be due to variation in exposure to NTS. To further support this hypothesis, it would be interesting to assess the kinetics of IgM since both anti-Typhimurium IgG and IgM can demonstrate bactericidal activity (Goh
<italic>et al.</italic>, 2016
<sup><xref rid="rep-ref-27468-2" ref-type="bibr">2</xref></sup>). If these titers are available, it would add a thought-provoking element to the data set.</p></list-item><list-item><p>Please state the statistical test used to compare groups.</p></list-item><list-item><p>Serovars do not need to be italicized.</p></list-item><list-item><p>Panels A and B are blurry, and the font size for the axes is small. Please add a label to the x-axis of panels C and D.</p></list-item></list>
</p><p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p></body><back><ref-list><title>References</title><ref id="rep-ref-27468-1"><label>1</label><mixed-citation publication-type="journal">
:
<article-title>Immunogenicity of a Bivalent Adjuvanted Glycoconjugate Vaccine against Salmonella Typhimurium and Salmonella Enteritidis.</article-title>
<source><italic toggle="yes">Front Immunol</italic></source>.<year>2017</year>;<volume>8</volume>:
<elocation-id>10.3389/fimmu.2017.00168</elocation-id>
<fpage>168</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.00168</pub-id>
<?supplied-pmid 28289411?><pub-id pub-id-type="pmid">28194151</pub-id></mixed-citation></ref><ref id="rep-ref-27468-2"><label>2</label><mixed-citation publication-type="journal">
:
<article-title>Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.</article-title>
<source><italic toggle="yes">PLoS Negl Trop Dis</italic></source>.<year>2016</year>;<volume>10</volume>(<issue>4</issue>) :
<elocation-id>10.1371/journal.pntd.0004604</elocation-id>
<fpage>e0004604</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0004604</pub-id>
<?supplied-pmid 27057743?><pub-id pub-id-type="pmid">27057743</pub-id></mixed-citation></ref></ref-list></back></sub-article><sub-article id="report27467" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/gatesopenres.14147.r27467</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Alwis</surname><given-names>Ruklanthi</given-names></name><xref ref-type="aff" rid="r27467a1">1</xref><xref ref-type="aff" rid="r27467a2">2</xref><role>Referee</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2319-3701</contrib-id></contrib><aff id="r27467a1">
<label>1</label>Viral Research and Experimental Medicine Centre, SingHealth-Duke NUS, Singapore, Singapore</aff><aff id="r27467a2">
<label>2</label>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>7</month><year>2019</year></pub-date><permissions><copyright-statement>Copyright: &#x000a9; 2019 de Alwis R</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="peer-reviewed-article" id="d35e1120" ext-link-type="doi" xlink:href="10.12688/gatesopenres.13034.1"/><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>The study investigates the sero-prevalence of iNTS, serovar Typhimurium and Enteritidis in Uganda. The study further describes the sero-epidemiology by age and sex of these pathogens in Uganda. This is a very useful study since very little is known about the basic epidemiology of iNTS in the Uganda population.
<list list-type="bullet"><list-item><p>Since the authors&#x02019; main explanation for the observed differences in sero-prevalence between Malawi and Uganda are due to differences in the experimental assays used to quantify O-antigen IgG, it would be good to give more details of this in-house ELISA assay.&#x000a0;</p></list-item><list-item><p>Since some of the authors from the Malawi study are also authors of the present study, is it not possible to run some of the Uganda sera (probably the sera in the less than 18 months age group) on the older flow-cytometry technique described in the MacLennan
<italic>et al.</italic> (2008
<sup><xref rid="rep-ref-27467-1" ref-type="bibr">1</xref></sup>) paper?</p></list-item><list-item><p>I agree with the authors that very little is known about the most commonly circulating and disease-causing serovars of NTS in Uganda. However, it might be good to mention one or two&#x000a0;current literatures, such as Afema
<italic>et al.</italic> (2016
<sup><xref rid="rep-ref-27467-2" ref-type="bibr">2</xref></sup>), where they show that neither&#x000a0;
<italic>S.&#x000a0;</italic>Typhimurium nor&#x000a0;
<italic>S.&#x000a0;</italic>Enteritidis are commonly isolated NTS serovars in Uganda (while in Malawi, Typhimurium and Enteritidis together make up over 90% of NTS cases (Feasey
<italic>et al.</italic>, 2015
<sup><xref rid="rep-ref-27467-3" ref-type="bibr">3</xref></sup>)).</p></list-item><list-item><p>It wouldn&#x02019;t hurt to show a graph of the O-antigen IgG data in HIV-infected and age-matched healthy individuals.</p></list-item></list> &#x000a0;</p><p> Minor comments:
<list list-type="bullet"><list-item><p>Please add x-axis titles to Figure 1C and 1D.&#x000a0;</p></list-item><list-item><p>Font labelling on panels 1A and 1B is small. Increase the font size on Figure panels 1A and 1B to match the font size of panels 1C and 1D.</p></list-item><list-item><p>State the statistical test used to compare O-antigen IgG responses in females and males in Figure 1C and 1D.</p></list-item></list>
</p><p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body><back><ref-list><title>References</title><ref id="rep-ref-27467-1"><label>1</label><mixed-citation publication-type="journal">
:
<article-title>The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children.</article-title>
<source><italic toggle="yes">J Clin Invest</italic></source>.<year>2008</year>;<volume>118</volume>(<issue>4</issue>) :
<elocation-id>10.1172/JCI33998</elocation-id>
<fpage>1553</fpage>-<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1172/JCI33998</pub-id>
<?supplied-pmid 18357343?><pub-id pub-id-type="pmid">18357343</pub-id></mixed-citation></ref><ref id="rep-ref-27467-2"><label>2</label><mixed-citation publication-type="journal">
:
<article-title>Potential Sources and Transmission of Salmonella and Antimicrobial Resistance in Kampala, Uganda</article-title>.
<source><italic toggle="yes">PLOS ONE</italic></source>.<year>2016</year>;<volume>11</volume>(<issue>3</issue>) :
<elocation-id>10.1371/journal.pone.0152130</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0152130</pub-id>
</mixed-citation></ref><ref id="rep-ref-27467-3"><label>3</label><mixed-citation publication-type="journal">
:
<article-title>Three Epidemics of Invasive Multidrug-ResistantSalmonella Bloodstream Infection in Blantyre, Malawi, 1998&#x02013;2014</article-title>.
<source><italic toggle="yes">Clinical Infectious Diseases</italic></source>.<year>2015</year>;<volume>61</volume>(<issue>suppl 4</issue>) :
<elocation-id>10.1093/cid/civ691</elocation-id>
<fpage>S363</fpage>-<lpage>S371</lpage>
<pub-id pub-id-type="doi">10.1093/cid/civ691</pub-id>
</mixed-citation></ref></ref-list></back></sub-article><sub-article id="report27470" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/gatesopenres.14147.r27470</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Qingke</given-names></name><xref ref-type="aff" rid="r27470a1">1</xref><role>Referee</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9185-214X</contrib-id></contrib><aff id="r27470a1">
<label>1</label>University of Florida, Gainesville, FL, USA</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>9</day><month>7</month><year>2019</year></pub-date><permissions><copyright-statement>Copyright: &#x000a9; 2019 Kong Q</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="peer-reviewed-article" id="d35e1343" ext-link-type="doi" xlink:href="10.12688/gatesopenres.13034.1"/><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>This is an ELISA assay to measure the antibodies against O-antigen from S. Typhimurium and Enteritidis from clinical sera collected from patents in Uganda. I do not have scientific questions about this assay, but hope in the future, that the authors could establish a standardized method to figure out the reason for the controversy obtained from two locations. &#x000a0;</p><p> Some minor grammar errors:
<list list-type="order"><list-item><p>Please add a comma between &#x0201c;disease&#x0201d; and &#x0201c;suggesting&#x0201d; in: &#x0201c;&#x02026;corresponds with a fall in cases of iNTS disease suggesting that vaccines able to&#x02026;&#x0201d;.</p></list-item><list-item><p>A comma or conjunction words were missing in: &#x0201c;There was no clear difference in antibody levels between the sexes and the few HIV-infected individuals in the study did not have obviously different levels from uninfected subjects&#x0201d;.</p></list-item><list-item><p>&#x0201c;Typhimurium&#x0201d; does not need to be italic.</p></list-item></list>
</p><p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body><sub-article id="comment3191" article-type="response"><front-stub><contrib-group><contrib contrib-type="author"><name><surname>Elias</surname><given-names>Sean</given-names></name><aff/></contrib></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>9</day><month>7</month><year>2019</year></pub-date></front-stub><body><p>Thank you for your comments. I can confirm that we will be publishing the optimised standardised ELISA protocol in the near future and will fully address the issues that you have highlighted.</p></body></sub-article></sub-article></article>